Prevalence of FRAX risk factors and the osteoporosis treatment gap among women ≥ 70 years of age in routine primary care across 8 countries in Europe.
Fracture Risk Assessment Tool (FRAX)
Fragility fracture
Observational study
Osteoporosis
Risk factors
Treatment gap
Journal
Archives of osteoporosis
ISSN: 1862-3514
Titre abrégé: Arch Osteoporos
Pays: England
ID NLM: 101318988
Informations de publication
Date de publication:
22 01 2022
22 01 2022
Historique:
received:
23
07
2021
accepted:
06
12
2021
entrez:
22
1
2022
pubmed:
23
1
2022
medline:
16
3
2022
Statut:
epublish
Résumé
We studied whether elderly women at risk for fractures receive primary care treatment to prevent fracture. We found that across Europe, women at risk are often not identified, and less than half of such women receive appropriate treatment. Finally, women diagnosed with osteoporosis are much more likely to receive treatment. To examine the relationship between risk factors for fragility fracture (FF) and osteoporosis (OP) treatment gap in elderly women across Europe, and compare the prevalence of risk factors between countries. Demographic and clinical information was collected from women ≥ 70 years visiting primary care physicians in Belgium, France, Germany, Ireland, Poland, Slovakia, Switzerland, and the UK. Increased risk of FF was defined by the presence of 1 or more criteria (history of fracture, 10-year fracture probability, or T-score ≤ - 2.5). There were 3798 women in total. Treatment gap (proportion at increased risk of FF not receiving treatment for OP) varied from 53.1 to 90.8% across countries, and the proportion of patients at increased risk of FF varied from 41.2 to 76.1%. Across countries, less than 50% of patients with increased risk of FF had a diagnosis of OP. Previous fracture was the most common risk factor, with similar prevalence across most countries; other risk factors varied widely. The treatment gap was reduced in patients with an OP diagnosis in all countries, but this reduction varied from 36.5 to 79.4%. The countries with the lowest rates of bone densitometry scans (Poland, France, and Germany; 8.3-12.3%) also had the highest treatment gap (82.2 to 90.8%). This study highlights differences across Europe in clinical risk factors for fracture, rates of densitometry scanning, and the rates of OP diagnosis. More emphasis is needed on risk assessment to improve the identification and treatment of elderly women at risk for fracture.
Identifiants
pubmed: 35064844
doi: 10.1007/s11657-021-01048-8
pii: 10.1007/s11657-021-01048-8
pmc: PMC8783912
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
20Subventions
Organisme : Medical Research Council
ID : MR/P020941/1
Pays : United Kingdom
Informations de copyright
© 2022. The Author(s).
Références
Compston JE, McClung MR, Leslie WD (2019) Osteoporosis (seminar). Lancet 393:364–376
doi: 10.1016/S0140-6736(18)32112-3
pubmed: 30696576
Tella H, Gallagher C (2014) Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol 142:155–170. https://doi.org/10.1016/j.jsbmb.2013.09.008
doi: 10.1016/j.jsbmb.2013.09.008
pubmed: 24176761
Borgström F, Karlsson L, Ortsäter G et al (2020) Fragility fractures in Europe: burden, management and opportunities. Arch Osteoporos 15:59. https://doi.org/10.1007/s11657-020-0706-y
doi: 10.1007/s11657-020-0706-y
pubmed: 32306163
pmcid: 7166207
Blain H, Masud T, Dargent-Molina P et al (2016) A comprehensive fracture prevention strategy in older adults: the European Union Geriatric Medicine Society (EUGMS) statement. J Nutr Health Aging 20(6):647–652. https://doi.org/10.1007/s12603-016-0741-y
doi: 10.1007/s12603-016-0741-y
pubmed: 27273355
pmcid: 5094892
Kanis JA, Harvey NC, Cooper C et al (2016) A systematic review of intervention thresholds based on FRAX: a report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos 11(1):25. https://doi.org/10.1007/s11657-016-0278-z
doi: 10.1007/s11657-016-0278-z
pubmed: 27465509
pmcid: 4978487
Rizzoli R (2018) Postmenopausal Osteoporosis: assessment and management. Best Pract Res Clin Endocrinol Metab 32(5):739–757. https://doi.org/10.1016/j.beem.2018.09.005
doi: 10.1016/j.beem.2018.09.005
pubmed: 30449552
Kanis JA, Cooper C, Rizzoli R et al (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30(1):3–44. https://doi.org/10.1007/s00198-018-4704-5
doi: 10.1007/s00198-018-4704-5
pubmed: 30324412
Chotiyarnwong P, Harvey NC, Johansson H et al (2019) Temporal changes in access to FRAX® in Thailand between 2010 and 2018. Arch Osteoporos 14(1):66
doi: 10.1007/s11657-019-0613-2
pubmed: 31227921
pmcid: 6588646
Kanis JA, Svedbom A, Harvey N, McCloskey EV (2014) The osteoporosis treatment gap. J Bone Miner Res 29(9):1926–1928. https://doi.org/10.1002/jbmr.2301
doi: 10.1002/jbmr.2301
pubmed: 24956507
Svedbom A, Hernlund E, Ivergård M et al (2013) Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos 8(1–2):137. https://doi.org/10.1007/s11657-013-0137-0
doi: 10.1007/s11657-013-0137-0
pubmed: 24113838
pmcid: 3880492
Svedbom A, Ivergård M, Hernlund E et al (2014) Epidemiology and economic burden of osteoporosis in Switzerland. Arch Osteoporos 9:187. https://doi.org/10.1007/s11657-014-0187-y
doi: 10.1007/s11657-014-0187-y
pubmed: 24970672
Cortet B, Chauvin P, Feron J-M et al (2020) Fragility fractures in France: epidemiology, characteristics and quality of life (the EPIFRACT study). Arch Osteoporos 15(1):46. https://doi.org/10.1007/s11657-019-0674-2
doi: 10.1007/s11657-019-0674-2
pubmed: 32170512
McCloskey E, Rathi J, Heijmans S et al (2021) The osteoporosis treatment gap in patients at risk of fracture in European primary care: a multi-country cross-sectional observational study. Osteoporos Int 32(2):251–259. https://doi.org/10.1007/s00198-020-05557-z
doi: 10.1007/s00198-020-05557-z
pubmed: 32829471
Compston J, Cooper A, Cooper C et al (2017) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 12(1):43. https://doi.org/10.1007/s11657-017-0324-5
doi: 10.1007/s11657-017-0324-5
pubmed: 28425085
pmcid: 5397452
Sattari M, Cauley JA, Garvan C et al (2017) Osteoporosis in the women’s health initiative: another treatment gap? Am J Med 130(8):937–948. https://doi.org/10.1016/j.amjmed.2017.02.042
doi: 10.1016/j.amjmed.2017.02.042
pubmed: 28366425
Balasubramanian A, Tosi LL, Lane JM, Dirschl DR, Ho PR, O’Malley CD (2014) Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009. J Bone Joint Surg Am 96(7):e52. https://doi.org/10.2106/JBJS.L.01781
doi: 10.2106/JBJS.L.01781
pubmed: 24695929
Kung AW, Fan T, Xu L et al (2013) Factors influencing diagnosis and treatment of osteoporosis after a fragility fracture among postmenopausal women in Asian countries: a retrospective study. BMC Womens Health 14(13):7. https://doi.org/10.1186/1472-6874-13-7
doi: 10.1186/1472-6874-13-7
Wang L, Yu W, Yin X et al (2021) Prevalence of osteoporosis and fracture in China: the China Osteoporosis Prevalence Study. JAMA Netw Open 4(8):e2121106. https://doi.org/10.1001/jamanetworkopen.2021.21106
doi: 10.1001/jamanetworkopen.2021.21106
pubmed: 34398202
pmcid: 8369359
Alami S, Hervouet L, Poiraudeau S et al (2016) Barriers to effective postmenopausal osteoporosis treatment: a qualitative study of patients’ and practitioners’ views. PLoS One 11(6):e0158365. https://doi.org/10.1371/journal.pone.0158365
doi: 10.1371/journal.pone.0158365
pubmed: 27355576
pmcid: 4927112
Merle B, Haesebaert J, Bedouet A et al (2019) Osteoporosis prevention: where are the barriers to improvement in French general practitioners? A qualitative study. PLoS One 14(7):e0219681. https://doi.org/10.1371/journal.pone.0219681
doi: 10.1371/journal.pone.0219681
pubmed: 31310619
pmcid: 6634405
Salminen H, Piispanen P, Toth-Pal E (2019) Primary care physicians’ views on osteoporosis management: a qualitative study. Arch Osteoporos 14:48. https://doi.org/10.1007/s11657-019-0599-9
doi: 10.1007/s11657-019-0599-9
pubmed: 31028556
pmcid: 6486622
Kanis JA, Norton N, Harvey NC et al (2021) SCOPE 2021: a new scorecard for osteoporosis in Europe. Osteoporos Int 16:82. https://doi.org/10.1007/s11657-020-00871-9
doi: 10.1007/s11657-020-00871-9
Morley J, Moayyeri A, Ali L et al (2020) Persistence and compliance with osteoporosis therapies among postmenopausal women in the UK Clinical Practice Research Datalink. Osteoporos Int 31(3):533–545. https://doi.org/10.1007/s00198-019-05228-8 (Epub 2019 Nov 22)
doi: 10.1007/s00198-019-05228-8
pubmed: 31758206
Hadji P, Kyvernitakis I, Kann PH et al (2016) GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab. Osteoporos Int 27:2967–2978
doi: 10.1007/s00198-016-3623-6
pubmed: 27172934
pmcid: 5042990
Raherison C, Girodet P-O (2009) Epidemiology of COPD. Eur Respir Rev 18:213–221
doi: 10.1183/09059180.00003609
pubmed: 20956146
Dennison EM, Compston JE, Flahive J et al (2012) Effect of comorbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone 50:1288–1293
doi: 10.1016/j.bone.2012.02.639
pubmed: 22426498
pmcid: 4886309
Lacruz ME, Kluttig A, Hartwig S et al (2015) Prevalence and incidence of hypertension in the general adult population: results of the CARLA-cohort study. Medicine 94(22):e952. https://doi.org/10.1097/MD.0000000000000952
doi: 10.1097/MD.0000000000000952
pubmed: 26039136
pmcid: 4616348
Mills KT, Bundy JD, Kelly TN et al (2016) Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation 134(6):441–450. https://doi.org/10.1161/CIRCULATIONAHA.115.018912
doi: 10.1161/CIRCULATIONAHA.115.018912
pubmed: 27502908
pmcid: 4979614
Banks J, Batty GD, Nazroo J et al. (eds). The dynamics of ageing. Evidence from the English Longitudinal Study of Ageing (ELSA), 2002–16 (WAVE 8). The Institute for Fiscal Studies (2018). Available from: https://www.ifs.org.uk/uploads/ELSA_Wave_8_report.pdf .
Shepstone L, Lenaghan E, Cooper C et al (2018) for SCOOP Study Team. Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. Lancet 391:741–747
doi: 10.1016/S0140-6736(17)32640-5
pubmed: 29254858